Cell & Genome Science Building R1706
400 Farmington Avenue
Farmington, CT 06032
RIGImmune is a platform preclinical biopharmaceutical startup that was founded in early 2020 out of
Yale University. We are developing a new class of therapeutic oligonucleotides called stem loop
RNAs (SLRs) that work by selectively activating a protein called retinoic acid inducible gene I (RIG-I).
RIG-I acts a surveillance system recognizing common molecular features of RNA viruses, and when
activated triggers the innate immune response.
RIGImmune’s lead compound RIG-101 has demonstrated preclinical efficacy, tolerability, and proof
of principle in multiple viral respiratory disease and oncology models. The company is pursuing IND
enabling activities for RIG-101 for use as an influenza treatment.
In 2022 the company announced acquisition of Subintro, a complementary biotech working to
develop antiviral therapeutics for respiratory RNA viruses. The acquisition provided RIGImmune
access to the company’s novel intranasal delivery formulations and expertise to drive its intranasal
broad spectrum antiviral program forward.
RIGImmune was awarded a Grant from the Bill and Melinda Gates Foundation through their Global
Influenza Challenge Project to study the use of our compounds as effective therapeutics against
influenza and to demonstrate the adjuvant potential of RIG-101 when co-administered or co-
formulated with the influenza vaccine. In addition to grant funding, RIGImmune has raised funds
from a series seed round of financing, an additional equity investment through the Gates Foundation
Strategic Investments Fund, and through investment from F prime Capital accompanying the
acquisition of its formulation company.